TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35410367
Drug: Orthoptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthoptic therapy (at least 2 months) including anti-suppression, vergence, and accommodation training
Study: 35410367
Drug: Orthoptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthoptic therapy
Study: 32407239
Drug: Combined histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined histamine H1/H2-receptor antagonists (Blockade)
Study: 33959852
Drug: Active oral
Normalized name: Factive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active oral orthotic (occlusal splint)
Study: 35881051
Drug: Belumosudil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belumosudil (200 mg)
Study: 35881051
Drug: Belumosudil (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belumosudil (1000 mg)
Study: 33743659
Drug: Depot medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot medroxyprogesterone acetate (DMPA) injection
Study: 34541744
Drug: 7-octave pure
Normalized name: Pure oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-octave pure tone sound therapy based on tinnitus characteristics
Study: 34541744
Drug: 9 one-third
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 one-third octave pure tone sound therapy based on tinnitus characteristics
Study: 32244296
Drug: Substrate Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substrate Reduction Therapy (SRT)
Study: 33709889
Drug: Matching-Adjusted Indirect
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching-Adjusted Indirect Comparisons for hematological and oncological treatments
Study: 32730561
Drug: Nonoperative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative management with antibiotics (n=370)
Study: 35393360
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indobufen two times daily
Study: 34007245
Drug: Spiritual wellbeing
Normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spiritual wellbeing assessment using the Functional Assessment of Chronic Illness Therapy‐Spiritual Well‐Being Scale‐12
Study: 32915892
Drug: Low-dose Combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Combination (2.5mg + 45mg for 2 weeks/5mg + 90mg for 10 weeks)
Study: 33724890
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia (H)
Study: 33724890
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia (H) + Virtual Reality distraction (VR)
Study: 33724890
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia (H) alone
Study: 36101515
Drug: Micellar curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micellar curcumin (105 mg day-1) for 7 days
Study: 36101515
Drug: Native curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native curcumin (105 mg day-1) for 7 days
Study: 36209239
Drug: Apalutamide in
Normalized name: Product containing apalutamide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide in addition to ongoing androgen deprivation therapy (ADT)
Study: 32593255
Drug: Plasma enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma enriched with platelets combined with traditional treatment
Study: 32593255
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment alone
Study: 35871950
Drug: OPF-105 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPF-105 (150 g dextrose, 60 g amino acids, 40 g fat, 1240 kcal per 2200 mL)
Study: 35871950
Drug: BFI (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFI (150 g dextrose, 60 g amino acids, 840 kcal per 2000 mL)
Study: 35871950
Drug: OPF-105 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPF-105 (multiple doses for 3 days)
Study: 35871950
Drug: BFI (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFI (multiple doses for 3 days)
Study: 33123091
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg oral iodine daily until delivery
Study: 37395101
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (CC)
Study: 32413774
Drug: G‐Lok™ with
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Lok™ with G‐Lok‐XL™ (fixed loop)
Study: 32413774
Drug: ProCinch™ with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProCinch™ with G‐Lok‐XL™ (adjustable loop)
Study: 32413774
Drug: G‐Lok™ (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Lok™ (control with socket tunnel)
Study: 35861301
Drug: Low-dose calcineurin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcineurin inhibitor (CNI) combined with sirolimus (SRL) after four weeks of standard regimen.
Study: 33964852
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of 3 whole Gala apples (∼200 g edible parts)/d for 6 weeks
Study: 33187518
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BJ) intake (140 mL, 12.8 mmol NO3‐)
Study: 32622603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CM without heat treatment)
Study: 36472579
Drug: liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 3.0 mg/day
Study: 36418131
Drug: Clinically assisted
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically assisted hydration (CAH) including parenteral fluids (dextrose saline 4% dextrose, 0.18% sodium chloride)
Study: 32766705
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) with treatment as usual (TAU)
Study: 35245661
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day allopurinol
Study: 33274199
Drug: Tablet candy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet candy
Study: 32966290
Drug: Praziquantel plus
Normalized name: moxidectin / praziquantel Oral Gel [Quest Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel plus Dihydroartemisinin-piperaquine combination
Study: 32657958
Drug: Spanish language
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish language TAPS Tool (self-administered)
Study: 32657958
Drug: Spanish language
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish language TAPS Tool (interviewer-administered)
Study: 35612354
Drug: Developing Inclusive
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developing Inclusive Youth program (classroom-based, individually administered video tool with teacher-led discussions)
Study: 33546968
Drug: Intraoperative fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative fluid (IOF) administration at a rate of 11.90 mL/kg/h (higher IOF rate)
Study: 33546968
Drug: Intraoperative fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative fluid (IOF) administration at a higher rate
Study: 33340263
Drug: Perampanel (2-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (2-12 mg/day)
Study: 33340263
Drug: Perampanel (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (8 mg/day)
Study: 32234295
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with Azacytidine (AZA) at 32 mg/m2 for 5 days every 28 days
Study: 32234295
Drug: Preemptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive treatment with Azacytidine (AZA) at 75 mg/m2 for 5 or 7 days per cycle
Study: 32234295
Drug: Donor lymphocyte
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor lymphocyte infusions (DLIs)
Study: 32234295
Drug: Treatment suspension
Normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment suspension
Study: 35945827
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model for diagnosing CRC using hemoglobin-to-platelet ratio, fibrinogen-albumin ratio (FAR), albumin-globulin ratio (A/G), platelet-lymphocyte ratio, carcinoembryonic antigen (CEA), and thrombin time (TT).
Study: 35945827
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model for diagnosing CRC stage using prothrombin time (PT), TT, CEA, A/G, FAR, and hemoglobin-to-platelet ratio (HPR).
Study: 35945827
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model for diagnosing CRC grade using PT, TT, A/G, plateletcrit, FAR, and HPR.
Study: 33637074
Drug: Parenteral ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Parenteral ibuprofen
Study: 33608400
Drug: Inhaled sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sedation strategy
Study: 33608400
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation strategy
Study: 33065813
Drug: Lurasidone 20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20-60 mg/d
Study: 34294144
Drug: Baidu Jieduan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baidu Jieduan granules (twice a day for 14 days)
Study: 34518313
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg orally twice daily and capivasertib orally twice daily on a 4-day on 3-day off schedule (DL1: 400 mg, DL-1: 320 mg)
Study: 34518313
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg orally twice daily and capivasertib orally twice daily on a 4-day on 3-day off schedule
Study: 32819292
Drug: Extracorporeal blood
Normalized name: Extracorporeal blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal blood purification (hemoadsorption) via resin-directed hemoperfusion using continuous renal replacement therapy (CVVH) for three sessions
Study: 32381160
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg or placebo administered subcutaneously every 2 weeks, titrated to 150 mg if LDL-C remained ≥50 mg/dl.
Study: 33881579
Drug: Inhalation Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Anesthesia (INHA) with desflurane (DES)
Study: 33417284
Drug: Topical cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cetirizine 1% applied daily (1 mL) for 6 months
Study: 33417284
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution applied daily (1 mL) for 6 months
Study: 35843915
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg/kg and continuous infusion at 2 mg/kg/h)
Study: 35843915
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (continuous infusion at 1.5 gr/kg)
Study: 36113378
Drug: JR-142 at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JR-142 at 0.25 mg/kg
Study: 36113378
Drug: JR-142 at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JR-142 at 0.5 mg/kg
Study: 36113378
Drug: JR-142 at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JR-142 at 1.0 mg/kg
Study: 33713840
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care adapted for co-occurring disorders (CC-COD)
Study: 33621809
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 mcg, subcutaneously)
Study: 32819740
Drug: 20-minute session
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-minute session with a certified therapy dog and handler
Study: 32591475
Drug: Natalizumab 600
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab 600 mg
Study: 34138478
Drug: Hydrocortisone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (200 mg/d) for 7 days or until hospital discharge
Study: 32967151
Drug: Tetraselmis chuii
Normalized name: tetraselmis chui extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetraselmis chuii microalgae supplementation (200 mg per day)
Study: 32967151
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lactose powder 200 mg per day)
Study: 36279463
Drug: Proposed treatment
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed treatment in randomized experiments
Study: 36368915
Drug: Group P
Normalized name: High mobility group protein HMGI-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P (0 mg.kg-1 S-ketamine)
Study: 36368915
Drug: Group S0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S0.3 (0.3 mg.kg-1 S-ketamine)
Study: 36368915
Drug: Group S0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S0.5 (0.5 mg.kg-1 S-ketamine)
Study: 36368915
Drug: Group S0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S0.7 (0.7 mg.kg-1 S-ketamine)
Study: 34975349
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - Instruction of daily care (IDC) only
Study: 32064970
Drug: 0.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/day omega-3 fatty acids from a plant-based fatty acid supplement
Study: 34347895
Drug: articaine (4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: articaine (4% / 2 mL)
Study: 34347895
Drug: tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol (100 mg/2 mL)
Study: 34347895
Drug: dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone (8 mg/2 mL)
Study: 34743963
Drug: 5% nanoHAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% nanoHAP dental lotion
Study: 34743963
Drug: Placebo dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dental lotion
Study: 33323529
Drug: Poseltinib 5
Normalized name: Poseltinib
DrugBank: Poseltinib (DB16299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poseltinib 5 mg
Study: 33323529
Drug: Poseltinib 10
Normalized name: Poseltinib
DrugBank: Poseltinib (DB16299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poseltinib 10 mg
Study: 33323529
Drug: Poseltinib 30
Normalized name: Poseltinib
DrugBank: Poseltinib (DB16299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poseltinib 30 mg
Study: 35667569
Drug: Monthly pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly pegcetacoplan treatment (AM)
Study: 35667569
Drug: Bimonthly pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimonthly pegcetacoplan treatment (AEOM)
Study: 35719221
Drug: LSMT (unilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSMT (unilateral lumbar PA mobilization at L‐4)
Study: 35719221
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LSMT and SS
Study: 33855653
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg TID plus choline alphoscerate 600 mg BID
Study: 33855653
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg TID plus placebo BID
Study: 35951060
Drug: Aerosol inhalation
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol inhalation combined with a vibration expectoration machine
Study: 33829344
Drug: Lutetium-Octreotate (LO)
Normalized name: lutetium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutetium-Octreotate (LO) treatment
Study: 39695768
Drug: Olaparib (PARP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (PARP inhibitor)
Study: 35721170
Drug: XueBiJing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: XueBiJing treatment (100 ml, q12 h for 5–7 days)
Study: 35721170
Drug: XueBiJing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: XueBiJing treatment and Placebo treatment
Study: 34035871
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no LIPUS treatment).
Study: 34035871
Drug: Low-Intensity Pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Pulsed Ultrasound (LIPUS) treatment.
Study: 36252718
Drug: Dexamethasone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (24 mg intravenously, perioperatively)
Study: 33245746
Drug: Overall Cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall Cohort (Tofacitinib 10 mg BID predominantly)
Study: 36136830
Drug: Parent-adolescent treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-adolescent treatment group
Study: 36136830
Drug: Parent only
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent only treatment group
Study: 35389487
Drug: n-3-PUFA ethyl
Normalized name: N-ethyl-3-hydroxy-N,N-dimethylanilinium
DrugBank: Edrophonium (DB01010)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: n-3-PUFA ethyl esters (3.9 g/d)
Study: 33434676
Drug: Ceftolozane/tazobactam 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/tazobactam 3 g q8h
Study: 33434676
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g q8h
Study: 34332028
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2400 mg/day and working memory training for 25 days
Study: 32368942
Drug: Elastic bandage
Normalized name: elastic bandage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastic bandage treatment
Study: 33135094
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for smoking cessation and guideline-based inhaler pharmacotherapy for newly diagnosed patients
Study: 35075598
Drug: LLLT-MTA (Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLLT-MTA (Low Level Laser Therapy with MTA)
Study: 32703779
Drug: Pirfenidone plus
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone plus inhaled N-acetylcysteine 352.4 mg twice daily
Study: 32703779
Drug: Pirfenidone plus
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone plus inhaled N-acetylcysteine
Study: 32782200
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy alone (CTx)
Study: 32782200
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy (noTx)
Study: 32782200
Drug: Adjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoradiotherapy (CRT) with radiation dose ≥54 Gy
Study: 32926117
Drug: Transcranial Low-Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Low-Level Light Therapy (LLLT)
Study: 32926117
Drug: Sham Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Therapy
Study: 35544437
Drug: Text-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text-based intervention focused on non-vaccine-related COVID-19 preventive health measures
Study: 32084142
Drug: IFN Nebulization
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN Nebulization 2 (2 μg/kg)
Study: 32084142
Drug: IFN Nebulization
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN Nebulization 1 (1 μg/kg)
Study: 36471382
Drug: Teleconsultations by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teleconsultations by specialists for neurology and palliative medicine
Study: 33574009
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL LR-PRP injection (single dose)
Study: 33574009
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL LR-PRP injection (double dose)
Study: 33574009
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (single and double dose)
Study: 35339102
Drug: 700/35 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700/35 mg foslevodopa/foscarbidopa subcutaneous infusion over 24 h
Study: 35339102
Drug: 350/87.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350/87.5 mg LD/CD administered over 16 h followed by two 100/25 mg LD/CD oral doses
Study: 34104878
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CP) therapy
Study: 32558416
Drug: UDCA 5
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 5 mg/kg/dose every 12 hours orally with phototherapy
Study: 32558416
Drug: UDCA 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 7.5 mg/kg/dose every 12 hours orally with phototherapy
Study: 32517477
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (weekly for five consecutive weeks)
Study: 32517477
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (pre-treatment effect)
Study: 33971993
Drug: Pecan nuts
Normalized name: Pecan nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pecan nuts group (30 g/d of pecans + healthy diet)